1.
病理类型转化病例的部分信息（续表）
Information of patients showing histological transformation (continued)
| References | Age (yr) | Gender | Smoking history | Histological type (a) | EGFR mutation (b) | EGFR mutation (a) | ALK rearrangement (b) | ALK rearrangement (a) | Chemotherapy (b) | Chemotherapy (a) | TKI (b) | TKI (a) |
| M: male; F: female; N: without smoking history; Y: with smoking history; SCLC: small cell lung cancer; SCC: squamous cell carcinoma; LCNEC: large cell neuroendocrine carcinoma; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; TKI: tyrosine kinase inhibitor; -: mutation/rearrangement negative; +: mutation/rearrangement postive; NA: not applicable; a: after histological transformation; b: before histological transformation; NVB: vinorelbine; DDP: cisplatin; CTP-11: irinotecan; PEM: pemetrexed; GEM: gemcitabine; CBP: carboplatin; VP16: etoposid; PTX: paclitaxel; L-OHP: oxaliplatin; ADM: adriamycin; CTX: cyclophosphamide. *The patient accepted other chemotherapy besides the drug listed in this table. **The concrete type of mutation was not given. | ||||||||||||
| [2] | 67 | F | N | SCLC | NA | NA | + | + | NVB+DDP* | CPT-11 | Crizotinib; Alectinib | Alectinib |
| [5] | 53 | F | N | SCLC | - | - | + | + | PEM+DDP* | VP16+DDP; ADM+CTX+VP16 | Crizotinib; Ceritinib | None |
| [6] | 75 | M | Y | SCLC | 19del | 19del | NA | NA | NVB+DDP | VP16+CBP | Afatinib | None |
| [8] | 53 | F | N | SCLC | 19del | 19del | NA | NA | NA | VP16+DDP | Erlotinib | Erlotinib |
| 63 | F | N | SCLC | 19del | - | NA | NA | NA | VP16+DDP | Gefitinib | None | |
| 48 | M | N | SCLC | 19del | 19del | NA | NA | NA | VP16+DDP | Erlotinib | Erlotinib | |
| 42 | M | Y | SCLC | L858R | - | NA | NA | NA | VP16+DDP | Gefitinib | None | |
| 48 | F | Y | SCLC | 19del | 19del | NA | NA | NA | VP16+DDP | Erlotinib | Erlotinib | |
| 58 | M | Y | SCLC | 19del | T790M | NA | NA | NA | VP16+DDP | Erlotinib | Osimertinib | |
| 60 | M | N | SCLC | 19del | - | NA | NA | NA | VP16+DDP | Erlotinib | None | |
| [9] | 57 | F | N | SCLC | L858R | L858R | NA | NA | PTX+CBP | VP16+DDP | Gefitinib; Afatinib | None |
| 54 | F | N | SCLC | 19del | 19del | NA | NA | PEM+DDP | GEM+DDP | Afatinib | None | |
| 55 | F | N | SCLC | 19del | 19del | NA | NA | None | VP16+DDP | Gefitinib | None | |
| 59 | F | N | SCLC | 19del | 19del | NA | NA | PEM+DDP | None | Gefitinib | Rociletinib | |
| 68 | F | N | SCLC | - | - | NA | NA | PEM+DDP | None | Gefitinib | None | |
| 67 | M | Y | SCLC | - | - | NA | NA | None | None | None | None | |
| [10] | 63 | M | Y | SCLC | 19del | 19del | NA | NA | None | VP16+CBP* | Erlotinib | Erlotinib; Osimertinib |
| [11] | 58 | F | N | SCLC | 19del | 19del | NA | NA | GEM+DDP* | VP16+CBP | Icotinib | Icotinib |
| [12] | 60 | F | NA | SCLC | L858R | L858R | NA | NA | None | None | Gefitinib | Crizotinib; Osimertinib |
| [13] | 43 | F | NA | SCLC | NA | NA | + | + | PEM+DDP* | NA | Crizotinib; Erlotinib; Alectinib | NA |
| [14] | 35 | M | N | SCLC | NA | NA | + | + | None | VP16+CBP | Ceritinib; Alectinib; Lorlatinib | Alectinib |
| [40] | 66 | F | N | SCC | 19exon** | 19exon** | NA | NA | PEM+CBP | NA | Erlotinib | NA |
| [42] | 68 | M | Y | SCC | L858R | L858R; T790M | NA | NA | Tegafur+Uracil; PEM+CBP | None | Erlotinib | Osimertinib |
| [43] | 44 | F | Y | SCC | 19del; T790M | 19del | - | - | None | None | Afatinib | Osimertinib |
| [44] | 79 | F | N | SCC | 19del | 19del | NA | NA | PEM+CBP | None | None | Erlotinib |
| [45] | 62 | M | N | SCC | L858R | L858R | NA | NA | Tegafur+Uracil | PEM+DDP | Gefitinib | None |
| [46] | 43 | F | Y | SCC | L858R | L858R; S768I | - | NA | None | None | Gefitinib | Gefitinib |
| [48] | 68 | M | N | LCNEC | L858R | L858R | NA | NA | NVB+DDP; PTX+CBP* | VP16;Amrubicin | Gefitinib; Erlotinib | None |
| [49] | 46 | M | N | LCNEC | 19del | 19del | NA | NA | GEM+DDP NVB+DDP | NA | Gefitinib; Erlotinib | NA |
| [50] | 57 | M | N | LCNEC | 19del | 19del | NA | NA | None | VP16+DDP | Erlotinib | Erlotinib; Osimertinib |
| [51] | 49 | M | N | SCLC | L858R; T790M | NA | NA | NA | Docetaxel+DDP; PEM+DDP | VP16+CBP CPT-11+L-OHP* | Gefitinib; Osimertinib | Apatinib |